Adapting versatile
polymers to improve
surgical outcomes
and patient recovery

Press Releases

05 September 2017

Polyganics Extends Global Distribution Network with the Addition of Multiple US Distributors

Groningen, The Netherlands, 5 September 2017 – Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices to promote peripheral nerve reconstruction and regeneration, announces the appointment of six US distributors for its peripheral nerve repair (PNR) portfolio.

New agreements with Southern Orthopaedics, Medex Surgical, Rascher Medical Solutions, Med Rep Corporation, South Coast Orthopedics and OJI Surgical will provide regional distribution of Polyganics’ PNR portfolio, which includes its NEUROCAP®, NEUROLAC®, and VIVOSORB® products. The portfolio uses Polyganics’ patented bioresorbable polymers to support nerve repair and recovery following surgery or injury.

read more

08 June 2017

Polyganics signs up multiple distributors in Europe to accelerate roll-out of Peripheral Nerve Repair portfolio

Groningen, The Netherlands, 8 June 2017 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has signed agreements with leading medical technology distributors in Europe, to meet the growing distribution demands for Polyganics’ Peripheral Nerve Repair (PNR) products.

read more

20 April 2017

Polyganics Announces Enrollment of the First Patient in its PROTECT NEURO Study

Groningen, The Netherlands, 20 April 2017 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has enrolled the first patient in its international PROTECT NEURO study to treat and prevent symptomatic neuroma. The first patient was treated at Stanford Medicine by Catherine Curtin, MD, associate professor of surgery.

read more

16 February 2017

Polyganics’ “STOP NEUROMA” Study Interim Data Shows Reduction in Pain

  • NEUROCAP® 3-month interim data show an average pain reduction of 84%
  • Final patient recruited in “STOP NEUROMA” clinical study, full data due to be reported by Q3 2018.

Groningen, The Netherlands 16 February 2017 – Polyganics, a privately held medical technology company, announced today that interim results show a sharp improvement in pain reduction observed across patients currently enrolled within the “STOP NEUROMA” study.

read more

07 December 2016

Polyganics announces Birmingham Hand Centre efficacy study of nerve conduit NEUROLAC® in finger surgery

  • NEUROLAC® nerve conduit to be evaluated in 170+ patient CONNECT study over 36 months, with interim results due in Q4 2017 and full results in H2 2019
  • Study centre – the Birmingham Hand Centre, part of the NHS’s Queen Elizabeth Hospital in Birmingham, a leading UK centre in hand and reconstructive surgery

Groningen, The Netherlands, 7 December 2016 – Polyganics, a privately held medical technology company focused on the development, manufacturing and commercialization of innovative bioresorbable medical devices that facilitate tissue repair and regeneration, announced today the launch of the CONNECT study, in collaboration with the Birmingham Hand Centre, part of the University Hospitals Birmingham NHS Foundation Trust in the UK. The study has been developed to deliver improvements in peripheral nerve repair after injury.

read more

21 June 2016

Polyganics Announces CE Mark for NEUROCAP®, the Nerve Capping Device for Treatment and Prevention of Symptomatic Neuroma

Groningen, The Netherlands, 21 June 2016 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has received the CE mark for NEUROCAP®, its nerve capping device. Polyganics intends to launch NEUROCAP® in several European countries later this year. 

read more

10 May 2016

Polyganics Announces Enrollment of First Patients in Multicenter Study for NEUROCAP Nerve Capping Device

Groningen, The Netherlands, 9 May 2016,  Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that the first four patients have been enrolled in the “STOP NEUROMA” study.

read more

15 March 2016

Polyganics appoints Dr Jan Öhrström to Supervisory Board

Groningen, The Netherlands, 15 March 2016 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve repair, neurosurgery, general surgery, as well as ear, nose & throat surgery, today announced it has appointed Dr Jan K. Öhrström to its Supervisory Board. The appointment is effective immediately.

 

read more

26 February 2016

Polyganics Receives Chinese Food and Drug Administration (CFDA) Approval for NEUROLAC®

Beijing, China, 26 February 2016 – Polyganics today announced it has received Chinese FDA (CFDA) clearance for NEUROLAC®, a unique synthetic and resorbable nerve conduit designed to support regeneration of peripheral nerve discontinuities up to 20 mm in patients who have sustained a complete division of a nerve.

read more

26 January 2016

Polyganics Receives FDA 510(k) Clearance for Nerve Capping Device NEUROCAP

Groningen, The Netherlands, 26 January 2016 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve repair, neurosurgery, general surgery, as well as ear, nose & throat surgery, today announced it has received FDA 510(k) clearance for NEUROCAP, an innovative device designed to reduce painful neuroma formation and thereby facilitate tissue repair and regeneration.

read more

21 January 2016

Polyganics and MicroAire sign exclusive distribution agreement for peripheral nerve repair portfolio in the US, Canada and Puerto Rico

Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve repair, neurosurgery, general surgery, as well as ear, nose & throat surgery, today announced it has signed an exclusive distribution agreement with its strategic partner MicroAire Surgical Instruments LLC for the company’s entire peripheral nerve repair (PNR) portfolio in the US, Canada and Puerto Rico.

read more

07 November 2014

Polyganics announces divestment of its ENT activities

Polyganics today announces it has signed an agreement to sell its activities in the field of Ear, Nose and Throat (ENT) surgery to Stryker. The ENT activities comprise a portfolio of sinunasal and otological dressings, including the marketed products NASOPORE®, HEMOPORE®, OTOPORE® and NASOPORE-FD®. As part of the agreement, Polyganics will continue to manufacture these products in the coming years.

read more

23 October 2014

Polyganics obtains FDA 510k clearance to market HEMOPORE®

Today, Polyganics announces it has obtained FDA clearance for HEMOPORE®. HEMOPORE® offers two forms of post-op hemostatic control in one bioresorbable sinunasal dressing. The clearance comes after the CE regulatory approval of NASOPORE FD® in April 2014 and FDA 510k approval of NASOPORE FD® in October 2014.

read more

07 August 2014

Polyganics obtains FDA 510k clearance to market NASOPORE-FD®

Today, Polyganics announces it has obtained FDA clearance for NASOPORE-FD®, a sinunasal dressing with a rapid clearance time. The clearance comes after the CE regulatory approval of NASOPORE-FD® in April 2014 and marks a next step in the commercialization Polyganics’ front-running bioresorbable nasal dressing portfolio marketed under the NASOPORE® brand.

read more

17 April 2014

Polyganics obtains CE approval to market NASOPORE-FD®

Polyganics today announces the CE regulatory approval of NASOPORE- FD®, a sinunasal dressing with a rapid clearance time. NASOPORE-FD® is the latest addition to Polyganics’ front-running bioresorbable nasal dressing portfolio marketed under the NASOPORE® brand. After insertion, NASOPORE-FD® exerts moderate elastic compression on the surrounding tissue for 36-48 hours while absorbing surrounding fluids.

read more

29 November 2012

Polyganics wins High Growth Award 2012

Today, Polyganics announces it has won the High Growth Award 2012. The High Growth Award is a prize for Dutch companies that combine growth, both in quality and quantity, with a clear vision of the future. Polyganics effectively proves that entrepreneurship and innovation continue to bear fruit, also in the current economic climate.

read more